Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
Senti Biosciences (NASDAQ: SNTI) has reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress and financial developments. The company's lead product SENTI-202 showed promising initial Phase 1 results, with 2 out of 3 relapsed/refractory AML patients achieving MRD negative complete remission at the lowest dose level, maintaining remission as of March 2025.
The company substantially strengthened its financial position through a $47.6 million PIPE financing led by Celadon Partners, with participation from notable investors. The net proceeds of $45.1 million are expected to extend the company's runway into 2026. Additionally, Senti Bio received $1.5 million from CIRM, bringing total grant funding to $6.4 million.
Financial results show cash and cash equivalents of $48.3 million as of December 31, 2024. Q4 R&D expenses decreased to $7.8 million from $9.1 million year-over-year, while G&A expenses reduced to $8.4 million from $9.3 million. The company reported a Q4 net loss of $0.6 million ($0.67 per share) and a full-year 2024 net loss of $52.8 million ($12.03 per share).
Senti Biosciences (NASDAQ: SNTI) ha riportato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando significativi progressi clinici e sviluppi finanziari. Il prodotto di punta dell'azienda, SENTI-202, ha mostrato risultati iniziali promettenti nella Fase 1, con 2 pazienti affetti da AML recidivante/refrattaria su 3 che hanno raggiunto la remissione completa negativa per MRD al livello di dose più basso, mantenendo la remissione fino a marzo 2025.
L'azienda ha notevolmente rafforzato la sua posizione finanziaria attraverso un finanziamento PIPE di 47,6 milioni di dollari guidato da Celadon Partners, con la partecipazione di investitori di rilievo. I proventi netti di 45,1 milioni di dollari sono previsti per estendere la durata dell'azienda fino al 2026. Inoltre, Senti Bio ha ricevuto 1,5 milioni di dollari da CIRM, portando il finanziamento totale a 6,4 milioni di dollari.
I risultati finanziari mostrano liquidità e equivalenti liquidi pari a 48,3 milioni di dollari al 31 dicembre 2024. Le spese di R&S del quarto trimestre sono diminuite a 7,8 milioni di dollari rispetto ai 9,1 milioni di dollari dell'anno precedente, mentre le spese generali e amministrative sono scese a 8,4 milioni di dollari dai 9,3 milioni di dollari. L'azienda ha riportato una perdita netta di 0,6 milioni di dollari nel quarto trimestre (0,67 dollari per azione) e una perdita netta per l'intero anno 2024 di 52,8 milioni di dollari (12,03 dollari per azione).
Senti Biosciences (NASDAQ: SNTI) ha informado sus resultados financieros del cuarto trimestre y del año completo 2024, destacando avances clínicos significativos y desarrollos financieros. El producto líder de la empresa, SENTI-202, mostró resultados iniciales prometedores en la Fase 1, con 2 de 3 pacientes con AML recaída/refractaria alcanzando remisión completa negativa para MRD en el nivel de dosis más bajo, manteniendo la remisión hasta marzo de 2025.
La empresa fortaleció sustancialmente su posición financiera a través de un financiamiento PIPE de 47.6 millones de dólares liderado por Celadon Partners, con la participación de inversores destacados. Se espera que los ingresos netos de 45.1 millones de dólares extiendan el camino de la empresa hasta 2026. Además, Senti Bio recibió 1.5 millones de dólares de CIRM, llevando el financiamiento total a 6.4 millones de dólares.
Los resultados financieros muestran efectivo y equivalentes de efectivo de 48.3 millones de dólares al 31 de diciembre de 2024. Los gastos de I+D del cuarto trimestre disminuyeron a 7.8 millones de dólares desde 9.1 millones de dólares en comparación con el año anterior, mientras que los gastos generales y administrativos se redujeron a 8.4 millones de dólares desde 9.3 millones de dólares. La empresa reportó una pérdida neta de 0.6 millones de dólares en el cuarto trimestre (0.67 dólares por acción) y una pérdida neta de 52.8 millones de dólares para el año completo 2024 (12.03 dólares por acción).
Senti Biosciences (NASDAQ: SNTI)는 2024년 4분기 및 연간 재무 결과를 발표하며 중요한 임상 진전과 재무 발전을 강조했습니다. 회사의 주요 제품인 SENTI-202는 초기 1상 결과가 유망하게 나타났으며, 3명의 재발/불응성 AML 환자 중 2명이 가장 낮은 용량 수준에서 MRD 음성 완전 관해를 달성하였고, 2025년 3월까지 관해를 유지했습니다.
회사는 Celadon Partners가 주도하는 4760만 달러의 PIPE 자금 조달을 통해 재무 상태를 크게 강화했으며, 저명한 투자자들이 참여했습니다. 4510만 달러의 순수익은 회사를 2026년까지 지원할 것으로 예상됩니다. 또한 Senti Bio는 CIRM으로부터 150만 달러를 받았으며, 총 보조금 자금은 640만 달러에 달합니다.
재무 결과는 2024년 12월 31일 기준으로 현금 및 현금성 자산이 4830만 달러임을 보여줍니다. 4분기 R&D 비용은 전년 대비 910만 달러에서 780만 달러로 감소했으며, G&A 비용은 930만 달러에서 840만 달러로 줄었습니다. 회사는 4분기 순손실이 60만 달러(주당 0.67달러)이며, 2024년 전체 연간 순손실은 5280만 달러(주당 12.03달러)라고 보고했습니다.
Senti Biosciences (NASDAQ: SNTI) a publié ses résultats financiers du quatrième trimestre et de l'année 2024, mettant en avant des progrès cliniques significatifs et des développements financiers. Le produit phare de l'entreprise, SENTI-202, a montré des résultats initiaux prometteurs lors de la phase 1, avec 2 patients sur 3 atteignant une rémission complète négative pour MRD au niveau de dose le plus bas, maintenant la rémission jusqu'en mars 2025.
L'entreprise a considérablement renforcé sa position financière grâce à un financement PIPE de 47,6 millions de dollars dirigé par Celadon Partners, avec la participation d'investisseurs notables. Les produits nets de 45,1 millions de dollars devraient prolonger la durée de vie de l'entreprise jusqu'en 2026. De plus, Senti Bio a reçu 1,5 million de dollars de CIRM, portant le financement total à 6,4 millions de dollars.
Les résultats financiers montrent des liquidités et équivalents de liquidités de 48,3 millions de dollars au 31 décembre 2024. Les dépenses de R&D du quatrième trimestre ont diminué à 7,8 millions de dollars contre 9,1 millions de dollars l'année précédente, tandis que les dépenses générales et administratives ont été réduites à 8,4 millions de dollars contre 9,3 millions de dollars. L'entreprise a déclaré une perte nette de 0,6 million de dollars au quatrième trimestre (0,67 dollar par action) et une perte nette pour l'année 2024 de 52,8 millions de dollars (12,03 dollars par action).
Senti Biosciences (NASDAQ: SNTI) hat seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und dabei bedeutende klinische Fortschritte sowie finanzielle Entwicklungen hervorgehoben. Das Hauptprodukt des Unternehmens, SENTI-202, zeigte vielversprechende erste Ergebnisse der Phase 1, wobei 2 von 3 Patienten mit rezidivierender/refraktärer AML bei der niedrigsten Dosisstufe eine MRD-negative vollständige Remission erreichten und diese Remission bis März 2025 aufrechterhielten.
Das Unternehmen hat seine finanzielle Position erheblich durch eine PIP-Finanzierung in Höhe von 47,6 Millionen Dollar, geleitet von Celadon Partners, mit der Beteiligung namhafter Investoren, gestärkt. Die Nettoerlöse von 45,1 Millionen Dollar sollen die Laufzeit des Unternehmens bis 2026 verlängern. Darüber hinaus erhielt Senti Bio 1,5 Millionen Dollar von CIRM, wodurch die Gesamtsumme der Fördermittel auf 6,4 Millionen Dollar steigt.
Die finanziellen Ergebnisse zeigen Barmittel und Barmitteläquivalente in Höhe von 48,3 Millionen Dollar zum 31. Dezember 2024. Die F&E-Ausgaben im vierten Quartal sanken auf 7,8 Millionen Dollar von 9,1 Millionen Dollar im Vorjahr, während die allgemeinen und administrativen Ausgaben auf 8,4 Millionen Dollar von 9,3 Millionen Dollar zurückgingen. Das Unternehmen meldete einen Nettoverlust von 0,6 Millionen Dollar im vierten Quartal (0,67 Dollar pro Aktie) und einen Nettoverlust für das gesamte Jahr 2024 von 52,8 Millionen Dollar (12,03 Dollar pro Aktie).
- 2 out of 3 AML patients achieved complete remission in Phase 1 trial
- Successfully raised $47.6M in PIPE financing extending runway into 2026
- Reduced Q4 R&D expenses by 14.3% year-over-year
- Reduced Q4 G&A expenses by 9.7% year-over-year
- Secured additional $1.5M from CIRM grant
- Full-year 2024 net loss of $52.8 million
- Significant quarterly net loss of $0.67 per share
Insights
The initial Phase 1 data from SENTI-202 represents a noteworthy development in AML treatment. Complete remission in 2 out of 3 relapsed/refractory AML patients at the lowest dose level is particularly promising, as dose escalation typically improves response rates. More significantly, these remissions were MRD negative, meaning no detectable cancer cells remained using sensitive detection methods.
For context, relapsed/refractory AML typically has poor outcomes with conventional therapies, with complete remission rates often below 30% and median survival measured in months. The durability of response (patients maintaining remission) is especially encouraging, as AML often relapses quickly.
SENTI-202's gene circuit-enabled CAR-NK approach represents a differentiated mechanism from traditional chemotherapy and even standard CAR-T approaches. The favorable safety profile noted is consistent with NK cell therapies, which typically cause fewer cytokine-related toxicities than CAR-T therapies.
While these results come from a very small patient cohort and early trial phase, achieving MRD-negative CRs at the lowest dose schedule suggests potential for improved efficacy at higher doses. This could position SENTI-202 as a meaningful advance for AML patients with options.
Senti's Q4 financials and recent financing activities significantly strengthen its position. The
The balance sheet shows
Q4 net loss narrowed dramatically to
The promising early clinical data could accelerate partnership opportunities and potentially validate Senti's broader gene circuit platform. With cash through 2026 and encouraging initial efficacy signals, Senti has effectively de-risked near-term financial concerns while establishing proof-of-concept for its technology.
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission –
– Strengthened balance sheet with gross proceeds of approximately
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights.
“With initial data from the clinical trial of SENTI-202, we are getting a glimpse into the potential profile of our gene circuit-enabled CAR-NK therapy for patients with AML. As we look toward 2025, we anticipate sharing additional data from this exciting trial," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. “We are also grateful to have continued support from our investors, including those who participated in our successful PIPE financing in December 2024, and we look forward to demonstrating the potential of our next-generation cell therapies in oncology.”
PIPELINE AND CORPORATE HIGHLIGHTS
SENTI-202 for AML: The Company previously announced initial data from its ongoing Phase 1 clinical trial of SENTI-202 (NCT06325748) for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ("AML").
As announced in December 2024, three AML patients had been treated at the lowest dose level (1.0 billion CAR+ NK cells per dose) and lowest dose schedule (3 doses per cycle) and two achieved complete remission ("CR"), confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells to normal ranges. In addition, both patients were assessed as measurable residual disease ("MRD") negative after treatment, which is defined as no detectable cancer cells present in a bone marrow sample by the most sensitive locally available method. As of this month, both patients remain in remission. Across all three patients for which data was announced, SENTI-202 was generally well-tolerated, with an adverse event profile consistent with the use of lymphodepleting chemotherapy in patients with AML.
Raised gross proceeds of
Received CIRM Grant funds for clinical development of SENTI-202: In January 2025, the Company also received an additional
Expanded senior leadership team: In February 2025, the Company announced the addition of strategic hires Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations.
Appointed Fran Schulz and Feng Hsiung to the Board of Directors ("Board"): In December 2024, Fran Schulz was appointed to the Board. She has finance, strategic planning, operations, and transactions expertise in the life sciences industry. She serves as chairperson of the Board’s Audit Committee. In March 2025, Feng Hsiung was appointed to the Board and as a member of the Audit Committee. He has extensive business, finance, and investment experience from a career that included investment and portfolio management as well as investment banking.
FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
- Cash and Cash Equivalents: As of December 31, 2024, Senti Bio held cash and cash equivalents of
$48.3 million . - R&D Expenses: Research and development expenses were
$7.8 million for the quarter ended December 31, 2024, compared to$9.1 million for the same period in 2023. The decrease was primarily related to a reduction in headcount as the Company streamlined operations to prioritize SENTI-202 in 2024. For the full year of 2024, research and development expenses were$34.4 million . - G&A Expenses: General and administrative expenses were
$8.4 million for the quarter ended December 31, 2024, compared to$9.3 million for the same period in 2023. The decrease was mainly attributed to a reduction in headcount. For the full year of 2024, general and administrative expenses were$26.3 million . - Net Loss: Net loss was
$0.6 million , or$0.67 per basic and diluted share, for the quarter ended December 31, 2024. Net loss for the full-year 2024 was$52.8 million , or$12.03 per share, including non-cash stock-based compensation expense of$1.8 million .
About Senti Bio
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, demonstrated MRD-negative complete remissions in 2 of 3 patients in initial clinical data as of September 19, 2024, with 4+ and 3+ month durability as of December 2, 2024. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example against solid tumor targets. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships.
Forward-Looking Statements
This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the future development of our clinical and pre-clinical pipeline, success of our SENTI-202 clinical trial and financial projections and future financial and operating results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio’s dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio’s grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
| Senti Biosciences, Inc. Unaudited Selected Consolidated Balance Sheet Data (in thousands) | ||||||
| December 31, | December 31, | |||||
| 2024 | 2023 | |||||
| Cash and cash equivalents | ||||||
| Total assets | 97,841 | 119,484 | ||||
| Total liabilities | 47,086 | 52,571 | ||||
| Series A redeemable convertible preferred stock | 25,106 | — | ||||
| Total stockholders’ equity | 25,649 | 66,913 | ||||
| Senti Biosciences, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Total revenue | $— | $— | $— | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 7,772 | 9,122 | 34,356 | 32,150 | ||||||||||||
| General and administrative | 8,395 | 9,305 | 26,370 | 37,176 | ||||||||||||
| Impairment of long-lived assets | — | 271 | 313 | 25,692 | ||||||||||||
| Total operating expenses | 16,167 | 18,698 | 61,039 | 95,288 | ||||||||||||
| Loss from operations | (16,167 | ) | (18,698 | ) | (61,039 | ) | (92,727 | ) | ||||||||
| Total other income (expense), net | 15,557 | 10 | 8,249 | 9,321 | ||||||||||||
| Net loss from continuing operations | (610 | ) | (18,688 | ) | (52,790 | ) | (83,406 | ) | ||||||||
| Net income from discontinued operations | — | (28 | ) | — | 12,348 | |||||||||||
| Net loss | (610 | ) | (18,716 | ) | (52,790 | ) | (71,058 | ) | ||||||||
| Other comprehensive loss | — | — | — | (1 | ) | |||||||||||
| Comprehensive loss | ) | ) | ) | ) | ||||||||||||
| Net loss per share from continuing operations, basic and diluted | ) | ) | ) | ) | ||||||||||||
| Net income per share, from discontinued operations basic and diluted | — | (0.01 | ) | — | 2.79 | |||||||||||
| Net loss per share, basic and diluted | ) | ) | ) | ) | ||||||||||||
| Weighted-average shares outstanding, basic and diluted | 4,661,085 | 4,465,736 | 4,595,946 | 4,437,106 | ||||||||||||
Senti Bio Contacts Investors: investors@sentibio.com Media: media@sentibio.com
FAQ
What are the initial results of SENTI-202's Phase 1 trial for AML treatment?
How much did Senti Bio (SNTI) raise in their December 2024 PIPE financing?
What was Senti Bio's (SNTI) net loss for Q4 2024?
How much cash does Senti Bio (SNTI) have as of December 31, 2024?
What was the total CIRM grant funding received by Senti Bio (SNTI) as of January 2025?
